Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil

Molecular and Cellular Biochemistry

Volumn 379, Issue 1-2, 2013, Pages 43-49

  Ebner, Bernd ^a   Ebner, Annette ^a   Reetz, Anna ^a   Böhme, Stefanie ^a   Schauer, Antje ^a   Strasser, Ruth H ^a   Weinbrenner, Christof ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Klinikum Hanau   (Germany)

Author keywords

Bolus application; Cardioprotection; Ischemia; Myocardial infarction; PDE5; Postconditioning

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CHELERYTHRINE; MITOGEN ACTIVATED PROTEIN KINASE; PROPIDIUM IODIDE; PROTEIN KINASE C; SILDENAFIL; VARDENAFIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG TREATMENT FAILURE; HEART HEMODYNAMICS; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; CARDIOTONIC AGENTS; CYCLIC GMP; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; IMIDAZOLES; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROTEIN KINASE C; PURINES; RATS; RATS, WISTAR; SULFONES; TRIAZINES;

RATTUS;

EID: 84878466853     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1625-7     Document Type: Article

References (31)

1. Sutherland EW, Rall TW (1958) Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem 232:1077-1091
2. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA (2005) cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96:100-109. doi: 10.1161/01.RES.0000152262.22968.72
3. Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52
4. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 13:29-35. doi: S1043276001005239
5. Lin CS, Lau A, Tu R, Lue TF (2000) Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 268:628-635. doi: 10.1006/bbrc.2000.2187
6. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 338:1397-1404. doi: 10.1056/NEJM199805143382001
7. Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P (2002) The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 40:2006-2012. doi: S0735109702025639
8. Perez NG, Piaggio MR, Ennis IL, Garciarena CD, Morales C, Escudero EM, Cingolani OH, de Chiappe CG, Yang XP, Cingolani HE (2007) Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 49:1095-1103. doi: 10.1161/HYPERTENSIONAHA.107.087759
9. Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101:1084-1095. doi: 10.1161/CIRCRESAHA.107.162511
10. Skyschally A, van CP, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G (2009) Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 104:469-483. doi: 10.1007/s00395-009-0040-4
11. Honisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C (2010) Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol 105:155-167. doi: 10.1007/s00395-009-0064-9
12. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, Kukreja RC (2007) Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 42:453-458. doi: 10.1016/j.yjmcc.2006.10.015
13. Maas O, Donat U, Frenzel M, Rutz T, Kroemer HK, Felix SB, Krieg T (2008) Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol 154:25-31. doi: 10.1038/bjp.2008.71
14. Salloum FN, Das A, Thomas CS, Yin C, Kukreja RC (2007) Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol 43:545-551. doi: 10.1016/j.yjmcc.2007.08.014
15. Wagner C, Ebner B, Tillack D, Strasser RH, Weinbrenner C (2013) Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats. J Cardiovasc Pharmacol 61:35-41. doi: 10.1097/FJC.0b013e3182760c4d
16. Ebner B, Lange SA, Eckert T, Wischniowski C, Ebner A, Braun-Dullaeus RC, Weinbrenner C, Wunderlich C, Simonis G, Strasser RH (2013) Uncoupled eNOS annihilates neuregulin-1beta-induced cardioprotection: a novel mechanism in pharmacological postconditioning in myocardial infarction. Mol Cell Biochem 373:115-123. doi: 10.1007/s11010-012-1480-y
17. Weinbrenner C, Schulze F, Sarvary L, Strasser RH (2004) Remote preconditioning by infrarenal aortic occlusion is operative via delta1-opioid receptors and free radicals in vivo in the rat heart. Cardiovasc Res 61:591-599. doi: 10.1016/j.cardiores.2003.10.008
18. Hiratsuka T (1982) New fluorescent analogs of cAMP and cGMP available as substrates for cyclic nucleotide phosphodiesterase. J Biol Chem 257:13354-13358
19. Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC (2009) ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296:H1236-H1243. doi: 10.1152/ajpheart.00100.2009
20. Das A, Smolenski A, Lohmann SM, Kukreja RC (2006) Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J Biol Chem 281:38644-38652. doi: 10.1074/jbc.M606142200
21. Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, Ockaili RA, Stasch JP, Kukreja RC (2012) Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol 302:H1347-H1354. doi: 10.1152/ajpheart.00544.2011
22. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955. doi: 10.1074/jbc.M404706200
23. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152. doi: 10.1124/mol.66.1.144
24. Mehrotra N, Gupta M, Kovar A, Meibohm B (2007) The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 19:253-264. doi: 10.1038/sj.ijir.3901522
25. Fernandes MA, Marques RJ, Vicente JA, Santos MS, Monteiro P, Moreno AJ, Custodio JB (2008) Sildenafil citrate concentrations not affecting oxidative phosphorylation depress H2O2 generation by rat heart mitochondria. Mol Cell Biochem 309:77-85. doi: 10.1007/s11010-007-9645-9
26. Castro LR, Schittl J, Fischmeister R (2010) Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res 107:1232-1240. doi: 10.1161/CIRCRESAHA.110.226712
27. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M, Rich TC (2006) Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 128:3-14
28. Ovize M, Baxter GF, Di LF, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R (2010) Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the working group of cellular biology of the heart of the European society of cardiology. Cardiovasc Res 87:406-423. doi: 10.1093/cvr/cvq129
29. Jaburek M, Costa AD, Burton JR, Costa CL, Garlid KD (2006) Mitochondrial PKC epsilon and mitochondrial ATP-sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res 99:878-883
30. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD (2006) The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 281:20801-20808. doi: 10.1074/jbc.M600959200
31. Das A, Xi L, Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585. doi: 10.1074/jbc.M801547200